On Monday, shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) marked $44.87 per share versus a previous $43.17 closing price. With having a 3.94% gain, an insight into the fundamental values of ACADIA Pharmaceuticals Inc., investors would also find a great ally in the technical patterns of the stock movements showed in stock charts. ACAD showed a rise of 4.89% within its YTD performance, with highs and lows between $30.02 – $58.72 during the period of 52 weeks, compared to the simple moving average of 1.91% in the period of the last 200 days.
Raymond James equity researchers changed the status of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares to a “Outperform” rating in the report published on August 25th, 2020. Other analysts, including Morgan Stanley, also published their reports on ACAD shares. Morgan Stanley repeated the rating from the previous report, marking ACAD under “Overweight” rating, in the report published on August 20th, 2020. Additionally, ACAD shares got another “Buy” rating from Stifel, setting a target price of $71 on the company’s shares, according to the report published in July 7th, 2020. On April 16th, 2020, Jefferies Initiated an Buy rating and increased its price target to $60. On the other hand, Goldman Upgrade the “Buy” rating for ACAD shares, as published in the report on March 31st, 2020. Citigroup seems to be going bullish on the price of ACAD shares, based on the price prediction for ACAD, indicating that the shares will jump to $69, giving the shares “Buy” rating based on their report from March 6th, 2020. Another “Buy” rating came from Guggenheim, providing a prediction for $69 price target according to the report published in December 16th, 2019.
[bold-text]ACADIA Pharmaceuticals Inc. (ACAD) Analysis[/bold-text]
The present dividend yield for ACAD owners is set at 0, marking the return investors will get regardless of the company’s performance in the upcoming period. In addition, the growth of sales from quarter to quarter is recording 32.30%, hinting the company’s progress in the upcoming progress.
In order to gain a clear insight on the performance of ACADIA Pharmaceuticals Inc. (ACAD) as it may occur in the future, there are more than several well-rounded types of analysis and research techniques, while equity is most certainly one of the more important indicators into the company’s growth and performance. In this case, you want to make sure that the return on the present equity of -33.50% is enough for you to make a profit out of your investment. You may also count in the quick ratio of the company, currently set at 8.40 so you would make sure that the company is able to cover the debts it may have, which can be easily seen in annual reports of the company.
Set to affect the volatility of a given stock, the average volume can also be a valuable indicator, while ACAD is currently recording an average of 1.17M in volumes. The volatility of the stock on monthly basis is set at 2.96%, while the weekly volatility levels are marked at 3.48%with 8.15% of gain in the last seven days. Additionally, long-term investors are predicting the target price of $59.33, indicating growth from the present price of $44.87, which can represent yet another valuable research and analysis points that can help you decide whether to invest in ACAD or pass.
[bold-text]What to Look for When Analyzing ACADIA Pharmaceuticals Inc. Shares?[/bold-text]
ACADIA Pharmaceuticals Inc. (ACAD) is based in the USA and it represents one of the well-known company operating with Healthcare sector. If you wish to compare ACAD shares with other companies under Electronic Equipment and Consumer Goods, a factor to note is the P/E value of for ACADIA Pharmaceuticals Inc., while the value can represent an indicator in the future growth of the company in terms of investor’s expectations. The later value should have a steady growth rate, increasing and growing gradually, which serves the purpose of reliably showcasing the progress of the company. The value -1.47 is supported by the yearly EPS growth of 17.50%.
Besides from looking into the fundamentals, you should also note the number of people inside the company owning the shares, as the values should be in line with the expectations of investors. In that spirit, the present ownership of stocks inside the company is set at 0.10%, which can provide you with an insight of how involved executives are in owning shares of the company. In oppose to the executives’ share, the institutional ownership counts 98.80% of shares, carrying an equal significance as an indicator of value, as the presence of large investors may signal a strong company.
[bold-text]Are Institutional Investors Increasing Stakes in ACAD Shares?[/bold-text]
It appears that more than several institutional investors and hedge funds decided to increase stakes in ACAD in the recent period. That is how Baker Bros. Advisors LP now has an increase position in ACAD by 0.00% in the first quarter, owning 41.9 million shares of ACAD stocks, with the value of $1.73 billion after the purchase of an additional 0 shares during the last quarter. In the meanwhile, Fidelity Management & Research Co also increased their stake in ACAD shares changed 2.42% in the first quarter, which means that the company now owns 20.73 million shares of company, all valued at $855.15 million after the acquisition of additional 489,787 shares during the last quarter.
Janus Capital Management LLC acquired a new position in ACADIA Pharmaceuticals Inc. during the first quarter, with the value of $161.29 million, and Citadel Advisors LLC increased their stake in the company’s shares by 4.45% in the first quarter, now owning 164,528 shares valued at $159.47 million after the acquisition of the additional 3.87 million shares during the last quarter. In the end, D. E. Shaw & Co. LP increased their position by 43.85% during the first quarter, now owning 2.15 million ACAD shares, now holding the value of $88.61 million in ACAD with the purchase of the additional 858,079 shares during the period of the last quarter. At the present, 98.80% of ACAD shares are in the ownership of institutional investors.